Human tissue considerations
What engages human tissue law when a product derives from human cells, and the cosmetics restriction on materials of human origin.
Where a product derives from human cells, questions arise that do not arise for animal or plant sources: whether the donor consented to this use, whether the donor was screened, whether the material is traceable from donor to recipient, and whether the establishments handling it hold the licences required.
There is also a specific point that is frequently missed. The list of substances prohibited in cosmetic products includes an entry covering cells, tissues and products of human origin. Any product of human origin presented as a cosmetic runs directly into that entry, and anyone relying on this point should read the current consolidated legislation rather than a summary.
Why human origin is a different question
Human material carries obligations that attach to its origin rather than to what is done with it. The person it came from had rights over it. Those rights are given effect through consent requirements, donor screening, traceability and the licensing of establishments that handle such material.
In the UK the Human Tissue Act 2004 and the regulations covering the quality and safety of tissues and cells intended for human application form the framework, with the Human Tissue Authority as regulator. Where material is substantially manipulated or intended for a different essential function than in the donor, it may instead fall within the advanced therapy medicinal product category regulated by the MHRA. Which applies is a determination on the facts.
The four questions
Consent
Did the donor consent to this use? Consent given for one purpose does not automatically extend to another, and consent for a therapeutic donation is not obviously consent for use as the starting material of a commercial cosmetic product. For a purchaser this is not a question they can verify directly, which is precisely why it is a question the supplier should be able to answer.
Screening
Was the donor screened for transmissible infection? Donor screening exists because material from one person going into another carries transmission risk, and this is standard practice in tissue and cell banking rather than an unusual precaution.
Traceability
Can the material be followed from donor to recipient and back? Traceability is what allows a recall to reach the right people. A product whose chain cannot be reconstructed cannot be recalled effectively, which matters most in exactly the circumstances where recall is needed.
Licensing
Are the establishments involved licensed for what they do? Procurement, testing, processing, storage and distribution of tissues and cells for human application are licensable activities, and the Human Tissue Authority publishes information on licensed establishments.
Products derived from human cells are outside human tissue regulation once the cells have been removed.
- Proposed mechanism
- Cell-free material is not tissue, so tissue law does not apply.
- What has been shown
- Whether a given derived material falls within a given framework is a determination on the facts, including the material's origin, the degree of manipulation and its intended use. The obligations attaching to human origin, including consent and traceability, are directed at the origin of the material, and we are not aware of any general exemption arising from cell removal alone.
- Highest level reached
- Not shown
- Main confounders
- Frameworks overlap and a product may sit in more than one. Determinations are product specific. Practice differs between jurisdictions.
GradeNOT ASSESSABLE
What would change thisA published determination or guidance addressing cell-free derivatives of human cells used in aesthetics specifically. Anyone relying on an exemption should be able to name the source establishing it, and that is a reasonable thing to ask a supplier for.
The cosmetics prohibition
Cosmetics legislation operates partly through annexes listing substances that are prohibited, restricted, or permitted only as specified. The prohibited list includes an entry covering cells, tissues and products of human origin.
The implication is direct: a product of human origin presented as a cosmetic runs into a prohibition that applies to cosmetic products, and the topical framing discussed in topical after microneedling does not avoid it, since that framing places the product within cosmetics legislation rather than outside it.
We flag this because it is the single most consequential regulatory point in the category and it is frequently absent from commercial discussion. We also flag, plainly, that we are describing a legislative provision rather than interpreting its application to any specific product, and that anyone relying on the point must read the current consolidated text and take advice. Legislation is amended.
| Source of material | Human tissue framework | Cosmetics prohibition on human origin |
|---|---|---|
| Human cells | Engages consent, screening, traceability, licensing | Directly relevant |
| Animal cells | Does not engage | Not applicable, other restrictions may apply |
| Plant material | Does not engage | Not applicable |
| Patient's own blood, prepared and returned | Different position, autologous use | Not applicable, no product placed on the market |
Why autologous preparations sit differently
Platelet preparations made from a patient's own blood and returned to that patient during the same procedure occupy a different position from a manufactured product placed on the market. There is no donor other than the patient, no product being supplied, and the questions become clinical and procedural rather than about market placement. This is one of the structural advantages of that category, noted in PRP and PRF.
It is not a general exemption, and the framing of autologous use has limits that vary with how much processing occurs and whether anything is added. As always, the determination is on the facts.
Where this leaves the reader
Human origin is not a marketing detail. It brings a framework with it, it brings a specific cosmetics prohibition into view, and it raises questions a purchaser cannot answer for themselves. Those are reasons to ask, not reasons to avoid the category, and a supplier with a properly documented chain has a genuine advantage they should be keen to demonstrate.
We record, for each supplier listed on this site, whether they disclose the origin of their material and the licensing position of their chain. Where they decline, we publish that they declined. That policy is set out in the rate card, and it is not purchasable.
Questions readers ask
Does human tissue law apply to cell-free products?
Whether a given material falls within a framework is a determination on the facts, including origin, degree of manipulation and intended use. We are not aware of any general exemption arising from removal of cells alone, and anyone relying on one should be able to name the source establishing it.
Are materials of human origin allowed in cosmetics?
The list of substances prohibited in cosmetic products includes an entry covering cells, tissues and products of human origin. Anyone relying on this point should read the current consolidated legislation, since annexes are amended.
What does traceability mean here?
The ability to follow material from donor through every processing stage to recipient and back. It exists so that if a safety problem emerges, everyone affected can be identified and reached.
Why is donor consent an issue?
Because consent given for one purpose does not automatically extend to another. Consent for a therapeutic donation is not obviously consent for use as starting material in a commercial cosmetic product, and a purchaser cannot verify this for themselves.
Is PRP treated the same way?
No. A preparation made from a patient's own blood and returned to that patient during the same procedure is not a product placed on the market and has no donor other than the patient, so the questions become clinical and procedural rather than about market placement.